Saul Sharkis, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died Sept. 4. He was 72.
John Christian Bailar III, an epidemiologist and biostatistician known for his criticism of NCI's emphasis on treatment, died Sept. 6. He was 83.
Vice President Joe Biden Sept. 16 announced a series of initiatives to improve the safety, accessibility, and impact of clinical research—one of the central goals of the National Cancer Moonshot Initiative.
Robert Westscott “Dr. Bob” Frelick died Sept. 1, 2016. He passed away in his sleep after an accident and short illness. He was 96.
NCI will urge increased and sustained appropriations for carrying out ten recommendations put forward by the Blue Ribbon Panel, the institute's scientific advisory panel to the National Cancer Moonshot Initiative.
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
Roger Tsien, co-winner of the 2008 Nobel Prize in chemistry and professor of pharmacology, chemistry and biochemistry at University of California San Diego School of Medicine for 27 years, died Aug. 24 in Eugene, Ore. He was 64.
The Association of American Cancer Institutes and the White House Cancer Moonshot Task Force are developing a new method for funding research at academic cancer centers through private investment and philanthropy.
Cellectar Biosciences Inc. received the second phase of an NCI Fast-Track Small Business Innovation Research contract award of $2 million to support funding of a phase II study of the company’s lead product candidate, CLR 131, for the potential treatment of hematologic malignancies, including multiple myeloma. The award will help fund a multi-center, open label […]
Advanced Accelerator Applications and NCI formed a clinical trial agreement: NCI plans to sponsor and conduct a study of Lutathera in patients with inoperable pheochromocytoma and paraganglioma. Pheochromocytoma is a rare endocrine tumor originating in the adrenal glands. Paraganglioma is a tumor that is closely related to pheochromocytoma and originates from outside the adrenal glands. […]
